Stanford Medicine researchers have created a scoring system based on resting brain scans that can evaluate an individual’s risk of cognitive decline and Alzheimer’s disease years before symptoms appear, according to a study published Nov. 4 in Science Advances.
The technique uses functional magnetic resonance imaging, or functional MRI, to record brain activity while a person lies quiet and still. By tracking how different brain regions communicate through blood oxygen levels, scientists identified patterns associated with cognitive resilience and vulnerability.
Comparing SuperAgers to Alzheimer’s Patients
To establish baseline patterns, the research team analyzed brain scans from two distinct groups of older adults: 180 SuperAgers—individuals aged 75 and older with memory performance comparable to adults decades younger—and 110 adults diagnosed with Alzheimer’s disease. The comparison revealed key functional connectivity differences between the two groups. Stronger connections involving the front of the brain were observed in SuperAgers, whereas connections involving the insula, a region located deep inside the brain, were stronger in participants with Alzheimer’s disease.
Using these distinctive patterns, researchers developed a measurement called the Alzheimer’s Resilience–Vulnerability Connectome, or ARC score. The ARC system distinguished SuperAgers from Alzheimer’s patients with approximately 85 percent accuracy in initial testing, Science Daily reported, and correctly categorized 71 percent of participants in an independent validation set, according to ScienceAlert.
Predicting Decline Years in Advance
The researchers then evaluated ARC scores for more than 1,300 cognitively healthy adults aged 55 to 70 who showed no initial cognitive impairment. Over follow-up periods extending up to 12 years, individuals with higher, more Alzheimer’s-like ARC scores experienced significantly faster cognitive decline on assessments of memory, attention, and executive function. They were also more likely to develop mild cognitive impairment or Alzheimer’s disease.
Additionally, follow-up imaging showed that amyloid beta protein accumulated faster in participants with higher ARC scores, even though participants started with similar protein levels. The scoring method outperformed established risk indicators—including age, genetic risk factors related to the APOE gene, and traditional biomarkers for tau and amyloid beta—in predicting future cognitive decline, Science Daily reported.
“Our model shows comparable or better prediction ability, and it can do so at an earlier time point,” Kanhao (Alex) Zhao, a postdoctoral scholar at Stanford Medicine and lead author of the study, told Science Daily. “And if we combine our score with the existing biomarkers, the prediction performance improves.”
Potential for Future Interventions
Unlike physical protein plaques, functional brain activity patterns can potentially be modified. Senior author Yu Zhang, an assistant professor of psychiatry and behavioral sciences at Stanford Medicine, noted that identifying resilient brain signatures provides a target for preventative strategies such as cognitive training or transcranial magnetic stimulation, which uses magnetic pulses to alter brain signals.
External experts welcomed the findings as a promising path toward early detection. Seán Kennelly, a consultant geriatrician and clinical director at Re:Cognition Health who was not involved in the study, told Medical News Today that studying SuperAgers gives valuable insight into what a healthy aging brain looks like and what makes some individuals vulnerable to Alzheimer’s disease.
Researchers emphasized that the ARC score is currently a research tool rather than a diagnostic test. Larger prospective studies across diverse populations and MRI scanners are still required before the system can be integrated into clinical decisions or used to enroll high-risk individuals in prevention trials.



